Stock Ratings / Health Care / FOCL / options

ELMD (77) HSDT (37) VANI (34) CV (44) ⌘ Pro Terminal →

EDAP TMS S.A. (FOCL) Options Positioning, Max Pain & Unusual Sweeps

Q: Is FOCL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, EDAP TMS S.A. (NASDAQ: FOCL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $4.17 (-2.11% 1D, market cap $191.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FOCL ranks #957 in composite RQD confidence.

Q: How does FOCL compare to ELMD and HSDT in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), FOCL carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 42.5%, and ROIC of -35.0%. By comparison, ELMD (Electromed Inc.) holds a B+ grade (77/100 RQD, P/E 30.4x, ROIC 24.1%, cap $229.4M) and HSDT (Solana Company (Class A)) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $146.5M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while ELMD leads on capital efficiency (24.1% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for FOCL?

Per FOCL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001041934), EDAP TMS S.A. generated $70.5M in revenue (+1.6% YoY), -$29.2M in net income, and -$16.4M in free cash flow against $79.0M in total assets and $15.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is FOCL trading relative to its 50-day, 200-day, and 52-week technical levels?

FOCL last traded at $4.17 (-2.11% on volume of 42,117 shares), positioning the stock -1.88% below its 50-day simple moving average ($4.25) and -5.44% below its 200-day simple moving average ($4.41). Across its 52-week range of $1.82 to $6.40, FOCL sits at the 51.3% percentile with a 14-day RSI of 47.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.65 to $4.69).

Q: What is FOCL's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for FOCL.

$4.17 -2.11% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.15

EDAP TMS S.A. (FOCL) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $191.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.15 (-0.57%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FOCL)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (29/100 Composite)

🔍 WHY FOCL SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Whale & Options Positioning+7/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$4.19-2.4% Next Q

Q2 (-2Q)

Grade E$4.09+2% Next Q

Q3 (-1Q)

Grade E$4.17+0% Next Q

Current

Grade E$4.17-9.8% Hist 90D α

Trajectory: E (37) → E (29)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FOCL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FOCL currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.25) and Max Pain ($4.38) forces dealer call-delta covering toward $6.72.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FOCL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “FOCL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 29%NO 71%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (FOCL)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for FOCL.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FOCL)

✓Walkthrough of FOCL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

FOCL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +25.60%⚡ TESTING RESISTANCE

2026-10-30O $4.30H $4.41L $4.10C $4.17VOL 66.1K

RES: $4.40SUP: $3.96SMA50: $4.25SMA200: $4.41

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FOCL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FOCL Butterfly Map → + Track FOCL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +1.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on FOCL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FOCL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for FOCL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FOCL)

Health Care Rank #957 of 1016 ⚔️ ELMD vs FOCL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FOCL vs. ELMD, HSDT, VANI, CV)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, EDAP TMS S.A. (FOCL) ranks #957 by composite RQD confidence (29/100, grade E) and #583 by equity capitalization ($191.6M). Within this direct 5-issuer industry benchmark cohort, VANI leads on earnings valuation at 3.9x trailing P/E, while ELMD leads on capital efficiency and profitability with 24.1% ROIC and 78.1% gross margin. ELMD currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with FOCL at 29/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
FOCL ACTIVE EDAP TMS S.A.	E	29/100	—	42.5%	-35.0%	-2.11%	$191.6M	Benchmark Subject
ELMD Electromed Inc.	B+	77/100	30.4x	78.1%	24.1%	+1.47%	$229.4M	/elmd-vs-focl →
HSDT Solana Company (Class A)	D-	37/100	—	96.0%	-35.0%	-1.31%	$146.5M	/hsdt-vs-focl →
VANI Vivani Medical Inc.	E	34/100	3.9x	—	-35.0%	0.00%	$102.8M	/vani-vs-focl →
CV CapsoVision Inc.	D	44/100	—	52.9%	-35.0%	-1.70%	$369.2M	/cv-vs-focl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001041934

In its most recent audited fiscal period (FY2025, filed 2025-12-31), EDAP TMS S.A. (FOCL) reported GAAP revenue of $70.5M (+1.6% vs. FY2024 revenue of $69.4M ) , GAAP net income of -$29.2M, operating cash flow of -$16.4M, and free cash flow of -$16.4M (-11.6% YoY). On the balance sheet, FOCL closed FY2025 with $79.0M in total assets against $15.9M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$70.5M	-$29.2M	-$16.4M	-$16.4M	$79.0M	$15.9M
FY2024 (FY)	2024-12-31	$69.4M	-$20.6M	-$14.7M	-$14.7M	$89.4M	$2.2M

3. FOCL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FOCL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, EDAP TMS S.A. (NASDAQ: FOCL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $4.17 (-2.11% 1D, market cap $191.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FOCL ranks #957 in composite RQD confidence.

How does FOCL compare to ELMD and HSDT in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), FOCL carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 42.5%, and ROIC of -35.0%. By comparison, ELMD (Electromed Inc.) holds a B+ grade (77/100 RQD, P/E 30.4x, ROIC 24.1%, cap $229.4M) and HSDT (Solana Company (Class A)) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $146.5M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while ELMD leads on capital efficiency (24.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FOCL?

Per FOCL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001041934), EDAP TMS S.A. generated $70.5M in revenue (+1.6% YoY), -$29.2M in net income, and -$16.4M in free cash flow against $79.0M in total assets and $15.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FOCL trading relative to its 50-day, 200-day, and 52-week technical levels?

FOCL last traded at $4.17 (-2.11% on volume of 42,117 shares), positioning the stock -1.88% below its 50-day simple moving average ($4.25) and -5.44% below its 200-day simple moving average ($4.41). Across its 52-week range of $1.82 to $6.40, FOCL sits at the 51.3% percentile with a 14-day RSI of 47.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.65 to $4.69).

FOCL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is FOCL's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for FOCL.

Direct Sub-Reports: FOCL RQD Cockpit FOCL 12M Forecast FOCL Earnings & Move FOCL Dividends & DRIP FOCL Insiders & 13F FOCL Whale Options FOCL Profit Sankey FOCL News & Why